The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis
===============================================================================================================================

* Abdullah N. Alkattan
* Nashwa M. Radwan
* Nagla E. Mahmoud
* Amjad F. Alfaleh
* Amal Alfaifi
* Khaled I. Alabdulkareem

## Abstract

This study aimed to predict the preventive effect of clopidogrel against recurrent cardiovascular events (CVEs) among the Arab population carrying different *CYP2C19* mutations and to determine the frequency of polymorphic alleles and genotypes of *CYP2C19* among them. The review included all the studies that reported data related to the *CYP2C19* polymorphisms among Arab populations. The review included Arab CVDs patients who are categorized into carriers (cases) and non-carriers (controls) of *CYP2C19* alleles and used clopidogrel as secondary prophylaxis. The patients who had recurrent CVEs or had high on-treatment platelet reactivity (HTPR) while using clopidogrel treatment were described as (events). The results showed a significantly increased risk of recurrent CVDs events by about three folds was associated with carriers of *CYP2C19*2* and *CYP2C19*3* mutations compared to non-carriers (OR= 3.32, CI=1.94-5.67, and OR=3.53, CI=1.17-10.63 respectively). However, no significant difference was recorded between both studied groups regarding the presence of *CYP2C19*17* mutation (OR=0.80, (CI=0.44-1.44). The results also revealed that 59 (4.16%) of Arabs carrying two *CYP2C19*2* alleles (homozygous), and 356 (25.12%) have one *CYP2C19*2* allele and one *CYP2C19*1* allele (heterozygous). Moreover, 42 (2.96%) were carrying two *CYP2C19*17* alleles (homozygous), and 262 (18.49%) were carrying one *CYP2C19*17* allele and one wild-type allele of *CYP2C19* (heterozygous). The most common *CYP2C19* genotypes reported among Arabs was the wild-type *\*1/\*1*, of which 49.26% of them had the homozygous form of the *CYP2C19*1* allele. The frequency of the CYP2C19*1 allele was 71.07%, followed by the *CYP2C19*2* allele (16.73%) and *CYP2C19*17* (12.21%), respectively. The *CYP2C19*3* allele was detected rarely among Arabs (<1%) compared to *CYP2C19*1, *2*, and **17* alleles. The present study revealed that Arabs carrying *CYP2C19*2* and *CYP2C19*3* alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs. Carriers of the *CYP2C19*17* allele, on the other hand, did not show a significant role either in increasing or decreasing the antiplatelet efficacy of clopidogrel. The *CYP2C19* genotypes including *\*1/\*1, \*1/\*2, \*1/\*17, \*2/\*2*, and *\*17/\*17* are commonly distributed among the Arabs.

Keywords
*   *CYP2C19* genotypes
*   Pharmacogenetics
*   clopidogrel
*   Arab population
*   platelet reactivity
*   cardiovascular events

## 1. Background

Patients with cardiovascular diseases (CVDs) are usually caused by a blood coagulation that blocks the cardiac vessels from supplying oxygen, glucose, minerals, and micro minerals to the cardiac tissues. Therefore, patients with CVDs should be subjected to antiplatelet or anticoagulant medications to avoid further coagulation. Otherwise, they will be at high risk of cardiovascular events (CVEs) in the future [1,2].

Clopidogrel is one of the medications that act as an antiplatelet by inhibiting the binding of adenosine diphosphate (ADP) to P2Y12 receptors, thus avoiding platelets adhesions and aggregations [3].

Clinically, clopidogrel is frequently used in Arab countries as a protective agent to avoid recurrent CVEs. However, several clinics did not have specific criteria to monitor the antiplatelet efficacy of clopidogrel either in the short or long term after the dispensation. Globally, the clinical efficacy of clopidogrel is controvertible, as most of the studies suggest that some genetic mutations among specific ethnicities are described as the causes of weak antiplatelet activity. Therefore, pharmacokinetics and pharmacodynamics studies have been conducted to reveal the basis of this issue.

The pharmacokinetic studies showed that clopidogrel prodrug needs to be activated by several metabolic enzymes. The clopidogrel agent is converted to 2-oxo-clopidogrel (inactive metabolite) by CYP1A2, CYP2C19, and CYP2B6 oxidative enzymes. The 2-oxo-clopidogrel is further converted to cis-thiol-clopidogrel (active metabolite) by CYP3A4, CYP2C19, CYP2C9 and CYP2B6 oxidative enzymes [4,5]. Therefore any mutation of these enzymes, including CYP2C19, could affect the metabolism of clopidogrel and consequently affect its plasma concentration levels and efficacy[6].

More than 30 mutations of *CYP2C19* have been identified [7]; however, only three polymorphic alleles are more familiar, including *CYP2C19*2, CYP2C19*3*, and *CYP2C19*17. CYP2C19*1* is encoding a normal active form of the CYP2C19 enzyme. *CYP2C19*2* and *CYP2C19*3* mutant alleles encode an inactive CYP2C19 enzyme, and the *CYP2C19*17* mutant allele is known to express a more active form of CYP2C19 enzyme [8].

Previous studies revealed that mutations of *CYP2C19* alleles are highly distributed among Asian people but lower among Europeans [9,10]. Nevertheless, the mutations of these alleles are not well studied among the Arab population. Therefore, this study aimed to investigate the efficacy of clopidogrel as an antiplatelet drug among those carrying these alleles and genotypes and determine the frequency of *CYP2C19* polymorphic alleles and genotypes among the Arab population.

## 2. Methods

### 2.1 Search methods

Two authors independently searched in PubMed, Google Scholar, and EMBASE databases for published English studies at any year related to clopidogrel efficacy and the frequency of *CYP2C19* gene polymorphism among Arabs. The exclusion criteria comprised non-Arab populations and patients with any contraindication for clopidogrel. The following terms were used in the search; *CYP2C19* Genotypes; OR *CYP2C19* Polymorphic alleles; OR *CYP2C19* Gene Mutations; AND clopidogrel response; OR Antiplatelet activity; AND Arabs.

### 2.3 Type of participants

This systematic review (for the qualitative part) included Arab people who were genotyped to determine the frequency of *CYP2C19* genotypes and alleles. Concerning the quantitative part (meta-analysis), only patients who previously had CVEs and using clopidogrel as secondary prophylaxis had been included. Those patients were categorized into carriers of (cases) and non-carriers (controls) of *CYP2C19* mutations, including *CYP2C19*2, CYP2C19*3*, and *CYP2C19*17*.

### 2.3 Outcome measures

The outcome of the quantitative part was to predict the antiplatelet efficacy of clopidogrel among carriers and non-carriers of *CYP2C19* mutations who previously had CVEs through measuring the frequency of the recurrent CVDs or high platelet aggregation reported. The outcome of the qualitative part was to determine the frequency of genotypes and alleles related to the *CYP2C19* gene among Arabs.

### 2.4 Data collection and extraction

Two authors independently reviewed the abstracts of potential articles for inclusion criteria and obtained all the relevant articles. Then, they extracted the following characteristics from the included studies; study setting, duration, design, participants’ age, sex, and outcome measures. Disagreement was solved by discussion.

### 2.5 Assessment of the risk of bias, quality of evidence, and treatment effect

Two authors independently assessed the risk of bias of the included studies. They graded each risk of bias as high, low, or unclear according to The Newcastle Ottawa Scale for non-randomized Studies [11]. According to the GRADE approach, the quality of evidence for each outcome measure was judged as high, moderate, low, or very low (Grading of Recommendations Assessment, Development, and Evaluation) [12]. The researchers analyzed the data using the Review Manager 5.3 program [13]. The risk of recurrent CVDS events was measured using Odds Ratio (OR) with 95% Confidence Interval (CI).

### 2.6 Dealing with heterogeneity

The I2 statistic was used to assess heterogeneity among the included studies in each analysis [14].

## 3. Results

### 3.1 Results of Search

One hundred and eighty-eight potentially relevant articles were searched, 97 were identified after the removal of duplicates. Two authors independently reviewed the abstracts of the articles based on inclusion and exclusion criteria. Nineteen full-text articles were assessed for eligibility; ten of them met the inclusion criteria (10 in qualitative and 6 in quantitative analysis). Details of the search are given in the PRISMA flow diagram (see figure.1)

![Figure.1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/02/02/2022.02.01.22270244/F1.medium.gif)

[Figure.1](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/F1)

Figure.1 PRISMA flow diagram

### 3.2 Included Studies

In the quantitative part, the review included 6 observational studies (2 retrospectives, 3 prospective, and one cross-section) [8,15–19], which reported data for clopidogrel antiplatelet efficacy in the presence of different *CYP2C19* gene variations.

On the other hand, the qualitative part included 10 studies, four case series, and six observational studies. These ten studies reported the frequency of *CYP2C19* polymorphisms among Arabs [20–23].

Two authors independently extracted characteristics of the included studies, including study title, journal, study design, duration, setting, aim, participants’ age, sex, number, and outcome measures (see table.1).

View this table:
[Table.1](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/T1)

Table.1 Characteristics of the included studies

### 3.3 Trial Participants

The quantitative part of the review included 878 Arabic (Saudis, Egyptians, Jordanians, Tunisians, Iraqis, and Palestinians) patients who were previously diagnosed with CVDs. For the qualitative part, 1417 Arabic people, either healthy or non-healthy, were included. The participants in the qualitative part originated from 7 different Arabic countries, including Saudi Arabia, Egypt, Jordan, Lebanon, Tunisia, Iraq, and Palestine.

### 3.4 Risk of bias among included Studies

Overall, no high risk of bias was recorded among the included studies in this review. Regarding {adequate case definition} bias and {comparability of cases and control} bias, it was unclear in Rjoub et al. study. Also, the {same representative rate for cases and control} bias was low risk in all included studies. While {consecutive representative of cases} and {independent outcome assessment} bias, it was unclear in most of the included studies (see figure.2).

![Figure.2](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/02/02/2022.02.01.22270244/F2.medium.gif)

[Figure.2](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/F2)

Figure.2 Risk of bias among included studies

### 3.5 Outcomes

#### 3.5.1 Outcomes of the quantitative part

Figures 3,4 and 5 presents the forest plots of the frequency of recurrent CVDs events among Arabic patients using clopidogrel either carrying or not carrying *CYP2C19*2, CYP2C19*3*, and *CYP2C19*17* mutations. The results showed a significantly increased risk of recurrent CVDs events by about three folds was associated with carriers of *CYP2C19*2* and *CYP2C19*3* mutations compared to non-carriers (OR= 3.32, CI=1.94-5.67, and OR=3.53, CI=1.17-10.63 respectively). However, no significant difference was recorded between both studied groups regarding the presence of *CYP2C19*17* mutation (OR=0.80, (CI=0.44-1.44).

![Figure.3](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/02/02/2022.02.01.22270244/F3.medium.gif)

[Figure.3](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/F3)

Figure.3 Forest plot of the frequency of recurrent CVDs among carriers and non-carriers of *CYP2C19*2* mutation.

![Figure.4](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/02/02/2022.02.01.22270244/F4.medium.gif)

[Figure.4](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/F4)

Figure.4 Forest plot of the frequency of recurrent CVDs among carriers and non-carriers of *CYP2C19*3* mutation.

![Figure.5](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/02/02/2022.02.01.22270244/F5.medium.gif)

[Figure.5](http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270244/F5)

Figure.5 Forest plot of the frequency of recurrent CVDs among carriers and non-carriers of *CYP2C19*17* mutation.

#### 3.5.2 Outcomes of the qualitative part

This part included 1417 Arabic people, which were genotyped in order to determine the *CYP2C19* gene variations and to detect the availability of any well-known mutated alleles, including *CYP2C19*2, CYP2C19*3*, and *CYP2C19*17* alleles among Arab populations, including Saudis, Egyptians, Jordanians, Iraqis, Palestinians, Lebanese and Tunisians people. The results revealed that 59 (4.16%) of them were carrying two *CYP2C19*2* alleles (homozygous), and 356 (25.12%) had one *CYP2C19*2* allele and one *CYP2C19*1* allele (heterozygous). Moreover, 42 (2.96%) were carrying two *CYP2C19*17* alleles (homozygous), and 262 (18.49%) were carrying one *CYP2C19*17* allele and one wild-type allele of

##### *CYP2C19* gene (heterozygous)

The most common CYP2C19 genotype reported among Arabs was the wild-type *\*1/\*1*, of which 49.26% of them had the homozygous form of the *CYP2C19*1* allele. The frequency of the *CYP2C19*1* allele was 71.07%, followed by the *CYP2C19*2* allele (16.73%) and *CYP2C19*17* (12.21%), respectively. The *CYP2C19*3* allele was detected rarely among Arabs (<1%) compared to *CYP2C19*1, *2*, and **17* alleles.

Based on the frequencies of genotypes, about half of Arab people (>49%) could be described as CYP2C19 extensive metabolizers. Other common *CYP2C19* gene phenotypes that existed among Arabs are intermediate metabolizers (25%), rapid metabolizers (18%), poor metabolizers (4%), and ultra-rapid metabolizers (3%), respectively.

## 4. Discussion

Many studies genotyped the *CYP2C19* gene to assess clopidogrel’s efficacy among specific ethnic groups. However, few studies correlated *CYP2C19* gene mutation and clopidogrel efficacy among Arab ethnic groups.

In the quantitative part, the present study recorded significant differences between carriers (cases) and non-carriers (controls) of *CYP2C19*2, *3* alleles regarding the number of recurrent CVEs in Arabs using clopidogrel (OR=3.32, CI=1.94, 5.67, and OR=3.53, CI=1.17, 10.63, respectively). However, there was no statistical difference among carriers and non-carriers of *CYP2C19*17* allele concerning the same aspect (OR=0.80, CI=0.44, 1.44).

These results indicate that Arab patients carrying *CYP2C19*2* and **3* alleles may decrease the antiplatelet activity of clopidogrel and could lead to recurrent CVEs. The present outcomes were consistent with more than 18 high-quality clinical trials and 6 meta-analysis studies. They revealed that *CYP2C19*2* and **3* alleles have a significant role in causing recurrent CVEs among patients using clopidogrel [24–43].

On the other hand, 3 previous meta-analysis studies concluded that loss-of-function alleles (*CYP2C19*2* and *CYP2C19*3*) have no significant effect in causing recurrent CVEs while using clopidogrel. However, they showed a significant effect in leading to other complications (e.g., ST-elevation and stent thrombosis) [44–46]. This could be explained by the presence of other genetic factors that may affect both the clopidogrel bioactivation process and recurrent CVEs, including specific *CYP2C9, CYP3A4, CYP1A2*, and *CYP2B6* genes’ mutations.

Concerning the qualitative part, the study revealed that CYP2C19 genotypes including *\*1/\*1, \*1/\*2, \*1/\*17, \*2/\*2*, and *\*17/\*17*, respectively, are commonly distributed among Arabs. Compared with other ethnic groups, the *CYP2C19*1* allele among Arabs was more or less similar to Caucasians (59.2%), Africans (70.2%), and Asians (65%). Also, the *CYP2C19*2* allele is similar to that of Caucasians (15.1%) and Africans (12.6%), but less than Asians (34.5%). The *CYP2C19*3* allele was rare among all ethnic groups, except Asians (9%). While the *CYP2C19*17* allele represented 12.2% among Arabs, it was recorded as the highest frequent mutant allele among the Caucasian population (25.7%), followed by the Africans (17.2%) and Asians (0.5%) [24].

## 5. Conclusions

The present study revealed that Arabs carrying *CYP2C19*2* and *CYP2C19*3* alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs. Carriers of the *CYP2C19*17* allele, on the other hand, did not show a significant role either in the increase or decrease of the antiplatelet efficacy of clopidogrel. The *CYP2C19* genotypes including *\*1/\*1, \*1/\*2, \*1/\*17, \*2/\*2*, and *\*17/\*17* are commonly distributed among the Arabs.

## Data Availability

All data produced in the present study are available upon reasonable request to the authors 

## Declarations

### Conflict of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

### Availability of data and material

The authors confirm that the data supporting the findings of this study are available within the article.

### Competing interests

The authors declare that there is no conflict of interest.

### Funding

Not funded.

## Author Contributions

AK and NR contributed in conceptualization. AK, NR and NM contributed in writing – original draft preparation. NM, AF, and KA contributed in writing – review and editing. NR, NM, AK, and AF contributed in resources. All authors have read and agreed to the published version of the manuscript.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Acknowledgments

The researchers would like to thank Dr. Yousef Almutairi (Saudi Ministry of Health, Riyadh, Saudi Arabia) for their assistance in reviewing the manuscript.

*   Received February 1, 2022.
*   Revision received February 1, 2022.
*   Accepted February 2, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## References

1.  1-.Malaguarnera, Giulia et al. “Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels.” Journal of thoracic disease vol. 9,8 (2017): 2332–2336.
    
    

2.  2-.Gradolí, Josep et al. “Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.” European cardiology vol. 13,2 (2018): 115–118.
    
    

3.  3-.Damman, Peter et al. “P2Y12 platelet inhibition in clinical practice.” Journal of thrombosis and thrombolysis vol. 33,2 (2012): 143–53.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11239-011-0667-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22183178&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

4.  4-.Frelinger AL 3rd., Bhatt DL et al. “Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.” Journal of the American College of Cardiology vol.61,8 (2013): 872–879.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjg6IjYxLzgvODcyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDIvMDIvMjAyMi4wMi4wMS4yMjI3MDI0NC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

5.  5-.Alkattan, A., & Alsalameen, E. (2021). Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. Expert opinion on drug metabolism & toxicology, 10.1080/17425255.2021.1925249. Advance online publication. [https://doi.org/10.1080/17425255.2021.1925249](https://doi.org/10.1080/17425255.2021.1925249)
    
    

6.  6-.Liu, Jian et al. “CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.” Chinese medical journal vol. 128,16 (2015): 2183–8.
    
    

7.  7-.Tabari, Robabeh Ghiyas et al. “Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.” Oman medical journal vol. 28,4 (2013): 237–44.
    
    

8.  8-.Alhazzani, Adel A et al. “Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.” Neurosciences (Riyadh, Saudi Arabia) vol. 22,1 (2017): 31–37.
    
    

9.  9-.Kim, Sollip et al. “Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.” Annals of laboratory medicine vol. 37,2 (2017): 180–193.
    
    

10. 10-.Han, Jun Hyun et al. “Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.” Asian journal of andrology vol. 17,2 (2015): 285–91.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4103/1008-682X.133320&link_type=DOI) 

11. 11-.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Ottawa (CN): Ottawa Hospital Research Institute; 2019
    
    

12. 12-.Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMzYvNzY1MC85MjQiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wMi8wMi8yMDIyLjAyLjAxLjIyMjcwMjQ0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

13. 13-.Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen; The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
    
    

14. 14-.Higgins JPT, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMjcvNzQxNC81NTciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wMi8wMi8yMDIyLjAyLjAxLjIyMjcwMjQ0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

15. 15-. Leila Abid et al. “Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region”. World Journal of Cardiovascular Diseases Vol.3 No.1,January 2013.
    
    

16. 16-.Al-Azzam, S. I., Alzoubi, K. H., Khabour, O. F., Nusair, M. B., Al-Hadidi, H., Awidi, A., & Saleh, A. (2013). Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach. International journal of clinical pharmacology and therapeutics, 51(3), 179–186. [https://doi.org/10.5414/CP201784](https://doi.org/10.5414/CP201784)
    
    

17. 17-.Ayesh, B. M., Al-Astal, I. R., & Yassin, M. M. (2019). The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. International journal of clinical pharmacy, 41(1), 96–103. [https://doi.org/10.1007/s11096-018-00782-3](https://doi.org/10.1007/s11096-018-00782-3)
    
    

18. 18-.Khalil BM et al. “Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.” Clin Transl Sci. 2016 Feb;9(1):23–8.
    
    

19. 19-.Mohammad, A. M., & Al-Allawi, N. (2018). CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention. Journal of cardiovascular pharmacology, 71(6), 347–351. [https://doi.org/10.1097/FJC.0000000000000577](https://doi.org/10.1097/FJC.0000000000000577)
    
    

20. 20-.Al, Jenoobi, Fahad I., et al. “CYP2C19 Genetic Polymorphism in Saudi Arabians.” Basic & Clinical Pharmacology & Toxicology, vol. 112, no. 1, Jan. 2013, pp. 50–54.
    
    

21. 21-. Malek Rjoub et al. “Allelic frequency of PON1 Q192R, CYP2C19*2 and CYP2C19*17 among Jordanian patients taking clopidogrel”. Tropical Journal of Pharmaceutical Research Vol 17 No 11 (2018).
    
    

22. 22-. Mostapha Ahmad et al. “Analysis of Gene Polymorphism CYP2C19 in the Lebanese Population Who Reside in Colombia”. Global Journal of Health Science; Vol. 10, No. 7; 2018.
    
    

23. 23-.Khalaf, Hassan et al. “Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.” Drug metabolism letters vol. 10,1 (2016): 65–70.
    
    

24. 24-.Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017;10:107–114 [https://doi.org/10.2147/PGPM.S126305](https://doi.org/10.2147/PGPM.S126305)
    
    

25. 25-.Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., & Sabatine, M. S. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. The New England journal of medicine, 360(4), 354–362. [https://doi.org/10.1056/NEJMoa0809171](https://doi.org/10.1056/NEJMoa0809171)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa0809171&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19106084&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000262519900007&link_type=ISI) 

26. 26-.Shuldiner, A. R., O’Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q., Pollin, T. I., Post, W., Parsa, A., Mitchell, B. D., Faraday, N., Herzog, W., & Gurbel, P. A. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302(8), 849–857. [https://doi.org/10.1001/jama.2009.1232](https://doi.org/10.1001/jama.2009.1232)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2009.1232&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19706858&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000269260100018&link_type=ISI) 

27. 27-.Harmsze, A., van Werkum, J. W., Bouman, H. J., Ruven, H. J., Breet, N. J., Ten Berg, J. M., Hackeng, C. M., Tjoeng, M. M., Klungel, O. H., de Boer, A., & Deneer, V. H. (2010). Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and genomics, 20(1), 18–25. [https://doi.org/10.1097/FPC.0b013e328333dafe](https://doi.org/10.1097/FPC.0b013e328333dafe)
    
    

28. 28-.Gong, I. Y., Crown, N., Suen, C. M., Schwarz, U. I., Dresser, G. K., Knauer, M. J., Sugiyama, D., DeGorter, M. K., Woolsey, S., Tirona, R. G., & Kim, R. B. (2012). Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. European heart journal, 33(22), 2856–2464a. [https://doi.org/10.1093/eurheartj/ehs042](https://doi.org/10.1093/eurheartj/ehs042)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehs042&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22374717&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000311303700018&link_type=ISI) 

29. 29-.Simon, T., Bhatt, D. L., Bergougnan, L., Farenc, C., Pearson, K., Perrin, L., Vicaut, E., Lacreta, F., Hurbin, F., & Dubar, M. (2011). Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clinical pharmacology and therapeutics, 90(2), 287–295. [https://doi.org/10.1038/clpt.2011.127](https://doi.org/10.1038/clpt.2011.127)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/clpt.2011.127&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21716274&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

30. 30-.Varenhorst, C., James, S., Erlinge, D., Brandt, J. T., Braun, O. O., Man, M., Siegbahn, A., Walker, J., Wallentin, L., Winters, K. J., & Close, S. L. (2009). Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European heart journal, 30(14), 1744–1752. [https://doi.org/10.1093/eurheartj/ehp157](https://doi.org/10.1093/eurheartj/ehp157)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehp157&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19429918&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

31. 31-.Sibbing, D., Gebhard, D., Koch, W., Braun, S., Stegherr, J., Morath, T., Von Beckerath, N., Mehilli, J., Schömig, A., Schuster, T., & Kastrati, A. (2010). Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of thrombosis and haemostasis : JTH, 8(8), 1685–1693. [https://doi.org/10.1111/j.1538-7836.2010.03921.x](https://doi.org/10.1111/j.1538-7836.2010.03921.x)
    
    

32. 32-.Kelly, R. P., Close, S. L., Farid, N. A., Winters, K. J., Shen, L., Natanegara, F., Jakubowski, J. A., Ho, M., Walker, J. R., & Small, D. S. (2012). Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British journal of clinical pharmacology, 73(1), 93–105. [https://doi.org/10.1111/j.1365-2125.2011.04049.x](https://doi.org/10.1111/j.1365-2125.2011.04049.x)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1365-2125.2011.04049.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21689142&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

33. 33-.Collet, J. P., Hulot, J. S., Anzaha, G., Pena, A., Chastre, T., Caron, C., Silvain, J., Cayla, G., Bellemain-Appaix, A., Vignalou, J. B., Galier, S., Barthélémy, O., Beygui, F., Gallois, V., Montalescot, G., & CLOVIS-2 Investigators (2011). High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC. Cardiovascular interventions, 4(4), 392–402. [https://doi.org/10.1016/j.jcin.2011.03.002](https://doi.org/10.1016/j.jcin.2011.03.002)
    
    

34. 34-.Jinnai, T., Horiuchi, H., Makiyama, T., Tazaki, J., Tada, T., Akao, M., Ono, K., Hoshino, K., Naruse, Y., Takahashi, K., Watanabe, H., Kita, T., & Kimura, T. (2009). Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circulation journal : official journal of the Japanese Circulation Society, 73(8), 1498–1503. [https://doi.org/10.1253/circj.cj-09-0019](https://doi.org/10.1253/circj.cj-09-0019)
    
    

35. 35-.Hochholzer, W., Trenk, D., Fromm, M. F., Valina, C. M., Stratz, C., Bestehorn, H. P., Büttner, H. J., & Neumann, F. J. (2010). Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. Journal of the American College of Cardiology, 55(22), 2427–2434. [https://doi.org/10.1016/j.jacc.2010.02.031](https://doi.org/10.1016/j.jacc.2010.02.031)
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjEwOiI1NS8yMi8yNDI3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDIvMDIvMjAyMi4wMi4wMS4yMjI3MDI0NC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

36. 36-.Jeong, Y. H., Kim, I. S., Park, Y., Kang, M. K., Koh, J. S., Hwang, S. J., Kwak, C. H., & Hwang, J. Y. (2010). Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC. Cardiovascular interventions, 3(7), 731–741. [https://doi.org/10.1016/j.jcin.2010.05.007](https://doi.org/10.1016/j.jcin.2010.05.007)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jcin.2010.05.007&link_type=DOI) 

37. 37-.Kang, M. K., Jeong, Y. H., Yoon, S. E., Koh, J. S., Kim, I. S., Park, Y., Hwang, S. J., Kwak, C. H., & Hwang, J. Y. (2010). Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention. Journal of atherosclerosis and thrombosis, 17(11), 1122–1131. [https://doi.org/10.5551/jat.4564](https://doi.org/10.5551/jat.4564)
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20724801&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

38. 38-.Bouman, H. J., Harmsze, A. M., van Werkum, J. W., Breet, N. J., Bergmeijer, T. O., Ten Cate, H., Hackeng, C. M., Deneer, V. H., & Ten Berg, J. M. (2011). Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart (British Cardiac Society), 97(15), 1239–1244. [https://doi.org/10.1136/hrt.2010.220509](https://doi.org/10.1136/hrt.2010.220509)
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6MTA6Ijk3LzE1LzEyMzkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wMi8wMi8yMDIyLjAyLjAxLjIyMjcwMjQ0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

39. 39-.Yamamoto, K., Hokimoto, S., Chitose, T., Morita, K., Ono, T., Kaikita, K., Tsujita, K., Abe, T., Deguchi, M., Miyagawa, H., Saruwatari, J., Sumida, H., Sugiyama, S., Nakagawa, K., & Ogawa, H. (2011). Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. Journal of cardiology, 57(2), 194–201. [https://doi.org/10.1016/j.jjcc.2010.10.007](https://doi.org/10.1016/j.jjcc.2010.10.007)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jjcc.2010.10.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21168310&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000288523800009&link_type=ISI) 

40. 40-.Kim, I. S., Jeong, Y. H., Park, Y., Yoon, S. E., Kwon, T. J., Park, J. R., Hwang, S. J., Koh, E. H., Kwak, C. H., Hwang, J. Y., & Kim, S. (2012). Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. British journal of clinical pharmacology, 73(4), 629–640. [https://doi.org/10.1111/j.1365-2125.2011.04131.x](https://doi.org/10.1111/j.1365-2125.2011.04131.x)
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22007612&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

41. 41-.Tang, X. F., Wang, J., Zhang, J. H., Meng, X. M., Xu, B., Qiao, S. B., Wu, Y. J., Chen, J., Wu, Y., Chen, J. L., Gao, R. L., Yuan, J. Q., & Yang, Y. J. (2013). Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. European journal of clinical pharmacology, 69(5), 1103–1112. [https://doi.org/10.1007/s00228-012-1446-8](https://doi.org/10.1007/s00228-012-1446-8)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00228-012-1446-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23150151&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

42. 42-.Wu, H., Qian, J., Xu, J., Sun, A., Sun, W., Wang, Q., & Ge, J. (2012). Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenetics and genomics, 22(12), 887–890. [https://doi.org/10.1097/FPC.0b013e328359253a](https://doi.org/10.1097/FPC.0b013e328359253a)
    
    

43. 43-.Zou, J. J., Xie, H. G., Chen, S. L., Tan, J., Lin, L., Zhao, Y. Y., Xu, H. M., Lin, S., Zhang, J., & Wang, G. J. (2013). Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. European journal of clinical pharmacology, 69(4), 771–777. [https://doi.org/10.1007/s00228-012-1392-5](https://doi.org/10.1007/s00228-012-1392-5)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00228-012-1392-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23001453&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 

44. 44-.Zabalza, M., Subirana, I., Sala, J., Lluis-Ganella, C., Lucas, G., Tomás, M., Masiá, R., Marrugat, J., Brugada, R., & Elosua, R. (2012). Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart (British Cardiac Society), 98(2), 100–108. [https://doi.org/10.1136/hrt.2011.227652](https://doi.org/10.1136/hrt.2011.227652)
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6ODoiOTgvMi8xMDAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wMi8wMi8yMDIyLjAyLjAxLjIyMjcwMjQ0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

45. 45-.Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P. (2011). CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA, 306(24), 2704–2714. [https://doi.org/10.1001/jama.2011.1880](https://doi.org/10.1001/jama.2011.1880)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2011.1880&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22203539&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F02%2F02%2F2022.02.01.22270244.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000298484000021&link_type=ISI) 

46. 46-.Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011). Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (Clinical research ed.), 343, d4588. [https://doi.org/10.1136/bmj.d4588](https://doi.org/10.1136/bmj.d4588)
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNDMvYXVnMDRfMS9kNDU4OCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzAyLzAyLzIwMjIuMDIuMDEuMjIyNzAyNDQuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)